missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ CD49a Monoclonal Antibody (TS2/7)

Description
MA49A0 targets CD49a in FACS, IHC(F), IP, and WB applications and shows reactivity with Human samples. The MA49A0 immunogen is human VLA-1 antigen. MA49A0 detects CD49a which has a predicted molecular weight of approximately 128 kDa.
Integrin alpha 1 (ITGA1) chain associates with the beta 1 (ITGB1) chain to form a heterodimer that functions as a dual laminin/collagen receptor in neural cells and hematopoietic cells. ITGA1 has a 206-amino acid I domain in its N-terminal half, followed by 3 divalent cation-binding sites and a C-terminal transmembrane domain with a short cytoplasmic tail. It also has 28 potential N-glycosylation sites. Human ITGA1 was expressed in a mouse fibroblast cell line as a 180-kD protein. ITGA1 is involved in the early remodeling of osteoarthritic cartilage and plays an essential role in the regulation of mesenchymal stem cell proliferation and cartilage production. It also plays an essential role in the regulation of MSC proliferation and cartilage production.
Specifications
Specifications
| Antigen | CD49a |
| Applications | Flow Cytometry, Immunohistochemistry (Frozen), Immunoprecipitation, Western Blot |
| Classification | Monoclonal |
| Clone | TS2/7 |
| Concentration | 20 μg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 0.5% BSA and 0.1% sodium azide |
| Gene | Itga1 |
| Gene Accession No. | P56199 |
| Gene Alias | CD49 antigen-like family member A; CD49a; E130012M19Rik; integrin alpha 1; integrin alpha-1; integrin subunit alpha 1; integrin, alpha 1; Itga1; Laminin and collagen receptor; very late activation protein 1; Vla1; VLA-1 |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?